alexa Alzheimer Disease And Human Consciousness: A Neurogenetic Connection
ISSN: 2155-9562

Journal of Neurology & Neurophysiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference and Exhibition on Neurology & Therapeutics
September 08-10, 2014 Hilton Philadelphia Airport, USA

John K Grandy
ScientificTracks Abstracts: J Neurol Neurophysiol
DOI: 10.4172/2155-9562.S1.017
Alzheimer disease (AD) is a neurodegenerative disorder that slowly erodes some of the facets of human consciousness. During the pathological course of AD beta-amyloid plaques form which causes damage to neurons and results in the gross loss of brain volume. As a consequence of AD, the afflicted individual develops decreases in cognitive/executive function, memory, and the ability to inhibit inappropriate behaviors. Another way of saying this is that the afflicted individual ceases to be the person that they once were, i.e., their degree of consciousness has deteriorated. Mutations in several genes, e.g. APP, PSEN1, PSEN2, and TREM2; and the gene variant APOE-epsilon4, have been correlated to the development of AD. This has given support to the idea that there are neurogenetic correlates of consciousness (NgCC). In previous works these NgCC have been delineated into three neurogenetic phases of human consciousness. AD is a primary example of gene-based neurodegeneration in the third neurogenetic phase. There is hope that symptoms of AD may be reversed with the development of novel genetic therapies. Some gene therapies are underway, e.g. FGF2, leptin, NEU1, and Klotho KL-VS gene therapies. If these gene therapies, or other genetic therapies, are successful in reversing some of the symptoms of AD, can they eventually be used to enhance human consciousness in individuals without AD?
image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version